Clinical utility of ustekinumab in Crohn’s disease

References

• BaumgartDCSandbornWJCrohn’s diseaseLancet201238098531590160522914295
   PubMed Web of Science ®Google Scholar
• FreemanHJNatural history and long-term clinical course of Crohn’s diseaseWorld J Gastroenterol2014201313624415855
   PubMed Web of Science ®Google Scholar
• GomollonFDignassAAnneseVECCO3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical managementJ Crohns Colitis201711132527660341
   PubMed Web of Science ®Google Scholar
• HanauerSBFeaganBGLichtensteinGRACCENT I Study GroupMaintenance infliximab for Crohn’s disease: the ACCENT I randomised trialLancet200235993171541154912047962
   PubMed Web of Science ®Google Scholar
• SandsBEAndersonFHBernsteinCNInfliximab maintenance therapy for fistulizing Crohn’s diseaseN Engl J Med2004350987688514985485
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trialGastroenterology20071321526517241859
   PubMed Web of Science ®Google Scholar
• SchreiberSKhaliq-KareemiMLawranceICPRECISE 2 Study InvestigatorsMaintenance therapy with certolizumab pegol for Crohn’s diseaseN Engl J Med2007357323925017634459
   PubMed Web of Science ®Google Scholar
• PanaccioneRColombelJFSandbornWJAdalimumab maintains remission of Crohn’s disease after up to 4 years of treatment: data from CHARM and ADHEREAliment Pharmacol Ther201338101236124724134498
   PubMed Web of Science ®Google Scholar
• LichtensteinGRYanSBalaMBlankMSandsBEInfliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s diseaseGastroenterology2005128486286915825070
   PubMed Web of Science ®Google Scholar
• RutgeertsPVan AsscheGSandbornWJAdalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trialGastroenterology2012142511021111.e222326435
   PubMed Web of Science ®Google Scholar
• QiuYChenBLMaoRSystematic review with meta-analysis: loss of response and requirement of anti-TNFalpha dose intensification in Crohn’s diseaseJ Gastroenterol201752553555428275925
   PubMed Web of Science ®Google Scholar
• TarganSRFeaganBGFedorakRNNatalizumab for the treatment of active Crohn’s disease: results of the ENCORE TrialGastroenterology200713251672168317484865
   PubMed Web of Science ®Google Scholar
• SandsBEFeaganBGRutgeertsPEffects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failedGastroenterology20141473618627.e324859203
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGRutgeertsPGEMINI 2 Study GroupVedolizumab as induction and maintenance therapy for Crohn’s diseaseN Engl J Med2013369871172123964933
   PubMed Web of Science ®Google Scholar
• PanaccioneRSandbornWJGordonGLBriakinumab for treatment of Crohn’s disease: results of a randomized trialInflamm Bowel Dis20152161329134025989338
   PubMed Web of Science ®Google Scholar
• BensonJMPerittDScallonBJDiscovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disordersMAbs20113653554522123062
   PubMed Web of Science ®Google Scholar
• FeaganBGSandbornWJGasinkCUNITI–IM-UNITI Study GroupUstekinumab as induction and maintenance therapy for Crohn’s diseaseN Engl J Med2016375201946196027959607
   PubMed Web of Science ®Google Scholar
• SandbornWJFeaganBGFedorakRNUstekinumab Crohn’s Disease Study GroupA randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s diseaseGastroenterology200813541130114118706417
   PubMed Web of Science ®Google Scholar
• SandbornWJGasinkCGaoLLCERTIFI Study GroupUstekinumab induction and maintenance therapy in refractory Crohn’s diseaseN Engl J Med2012367161519152823075178
   PubMed Web of Science ®Google Scholar
• SartorRBMechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitisNat Clin Pract Gastroenterol Hepatol20063739040716819502
   PubMedGoogle Scholar
• ColombelJFPanaccioneRBossuytPSuperior endoscopic and deep remission outcomes in adults with moderate to severe Crohn’s disease managed with treat to target approach versus clinical symptoms: data from calmGastroenterology20171525S155
   Web of Science ®Google Scholar
• de SouzaHSFiocchiCImmunopathogenesis of IBD: current state of the artNat Rev Gastroenterol Hepatol2016131132726627550
   PubMed Web of Science ®Google Scholar
• DeepakPLoftusEVJrUstekinumab in treatment of Crohn’s disease: design, development, and potential place in therapyDrug Des Devel Ther20161036853698
   PubMed Web of Science ®Google Scholar
• DamskerJMHansenAMCaspiRRTh1 and Th17 cells: adversaries and collaboratorsAnn N Y Acad Sci2010118321122120146717
   PubMed Web of Science ®Google Scholar
• PatelDDKuchrooVKTh17 cell pathway in human immunity: lessons from genetics and therapeutic interventionsImmunity20154361040105126682981
   PubMed Web of Science ®Google Scholar
• HarringtonLEHattonRDManganPRInterleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineagesNat Immunol20056111123113216200070
   PubMed Web of Science ®Google Scholar
• OppmannBLesleyRBlomBNovel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12Immunity200013571572511114383
   PubMed Web of Science ®Google Scholar
• VerstocktBVan AsscheGVermeireSFerranteMBiological therapy targeting the IL-23/IL-17 axis in inflammatory bowel diseaseExpert Opin Biol Ther2017171314727817215
   PubMed Web of Science ®Google Scholar
• SternASPodlaskiFJHulmesJDPurification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cellsProc Natl Acad Sci U S A19908717680868122204066
   PubMed Web of Science ®Google Scholar
• GublerUChuaAOSchoenhautDSCoexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factorProc Natl Acad Sci U S A19918810414341471674604
   PubMed Web of Science ®Google Scholar
• DaveMPapadakisKAFaubionWAJrImmunology of inflammatory bowel disease and molecular targets for biologicsGastroenterol Clin North Am201443340542425110250
   PubMed Web of Science ®Google Scholar
• PreskyDHYangHMinettiLJA functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunitsProc Natl Acad Sci U S A1996932414002140078943050
   PubMed Web of Science ®Google Scholar
• ParhamCChiricaMTimansJA receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23RJ Immunol2002168115699570812023369
   PubMed Web of Science ®Google Scholar
• LangrishCLChenYBlumenscheinWMIL-23 drives a pathogenic T cell population that induces autoimmune inflammationJ Exp Med2005201223324015657292
   PubMed Web of Science ®Google Scholar
• TengMWBowmanEPMcElweeJJIL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseasesNat Med201521771972926121196
   PubMed Web of Science ®Google Scholar
• DuerrRHTaylorKDBrantSRA genome-wide association study identifies IL23R as an inflammatory bowel disease geneScience200631458041461146317068223
   PubMed Web of Science ®Google Scholar
• BlancoPPaluckaAKPascualVBanchereauJDendritic cells and cytokines in human inflammatory and autoimmune diseasesCytokine Growth Factor Rev2008191415218258476
   PubMed Web of Science ®Google Scholar
• SarraMPalloneFMacdonaldTTMonteleoneGIL-23/IL-17 axis in IBDInflamm Bowel Dis201016101808181320222127
   PubMed Web of Science ®Google Scholar
• IzcueAHueSBuonocoreSInterleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitisImmunity200828455957018400195
   PubMed Web of Science ®Google Scholar
• ShenWDurumSKSynergy of IL-23 and Th17 cytokines: new light on inflammatory bowel diseaseNeurochem Res201035694094619915978
   PubMed Web of Science ®Google Scholar
• SandbornWGasinkCChanDPD-012 endoscopic healing in the ustekinumab phase 3 UNITI/IMUNITI Crohn’s disease program and relationship of clinical outcomes to baseline ulceration statusInflamm Bowel Dis201723S9
   Web of Science ®Google Scholar
• SandsBEGasinkCJacobsteinDFistula healing in pivotal studies of ustekinumab in Crohn’s diseaseGastroenterology2017152S185
   Web of Science ®Google Scholar
• BatistaDDYadavSHarmsenWSSu1420 ustekinumab treatment for Crohn’s disease in clinical practice: experience at a tertiary medical centerGastroenterology2014146S464S465
   Web of Science ®Google Scholar
• BattatRKopylovUBessissowTAssociation between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s diseaseClin Gastroenterol Hepatol201715914271434.e228365485
   PubMed Web of Science ®Google Scholar
• GreenupAJRosenfeldGBresslerBUstekinumab use in Crohn’s disease: a Canadian tertiary care centre experienceScand J Gastroenterol201752121354135928885058
   PubMed Web of Science ®Google Scholar
• HarrisKAHorstSGadaniAPatients with refractory Crohn’s disease successfully treated with ustekinumabInflamm Bowel Dis201622239740126752468
   PubMed Web of Science ®Google Scholar
• KhorramiSGinardDMarin-JimenezIUstekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohortInflamm Bowel Dis20162271662166927306072
   PubMed Web of Science ®Google Scholar
• KopylovUAfifWCohenASubcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease – the McGill experienceJ Crohns Colitis20148111516152224996483
   PubMed Web of Science ®Google Scholar
• MaCFedorakRNKaplanGGClinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohortAliment Pharmacol Ther20174591232124328252210
   PubMed Web of Science ®Google Scholar
• MaCFedorakRNKaplanGGLong-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn’s disease: real-world experience from a multicenter cohort studyInflamm Bowel Dis201723583383928328624
   PubMed Web of Science ®Google Scholar
• WilsPBouhnikYMichettiPGroupe d’Etude Thérapeutique des Affections Inflammatoires du Tube DigestifSubcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agentsClin Gastroenterol Hepatol2016142242250.e1–e226432476
   PubMed Web of Science ®Google Scholar
• HindryckxPBaertFHartAClinical Trial Committee Clincom of the European Crohn’s and Colitis Organisation (ECCO)Clinical trials in luminal Crohn’s disease: a historical perspectiveJ Crohns Colitis20148111339135024841216
   PubMed Web of Science ®Google Scholar
• ConcatoJShahNHorwitzRIRandomized, controlled trials, observational studies, and the hierarchy of research designsN Engl J Med2000342251887189210861325
   PubMed Web of Science ®Google Scholar
• HarveyRFBradshawJMA simple index of Crohn’s-disease activityLancet1980181675146102236
   PubMed Web of Science ®Google Scholar
• DaneseSBonovasSPeyrin-BirouletLPositioning ustekinumab in Crohn’s disease: from clinical evidence to clinical practiceJ Crohns Colitis201711101258126628575273
   PubMed Web of Science ®Google Scholar
• AbrahamCDulaiPSVermeireSLessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseasesGastroenterology20171522374388.e427780712
   PubMed Web of Science ®Google Scholar
• DeepakPSandbornWJUstekinumab and anti-interleukin-23 agents in Crohn’s diseaseGastroenterol Clin North Am201746360362628838418
   PubMed Web of Science ®Google Scholar
• FeaganBGSandbornWJD’HaensGInduction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 studyLancet2017389100801699170928411872
   PubMed Web of Science ®Google Scholar
• SandsBEChenJFeaganBGEfficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a phase 2a studyGastroenterology201715317786.e628390867
   PubMed Web of Science ®Google Scholar
• PappKABlauveltABukhaloMRisankizumab versus ustekinumab for moderate-to-severe plaque psoriasisN Engl J Med20173761551156028423301
   PubMed Web of Science ®Google Scholar